Molecular Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Puolakkainen, P. A.
Right arrow Articles by Sage, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Puolakkainen, P. A.
Right arrow Articles by Sage, E. H.
Molecular Cancer Research 2:215-224 (2004)
© 2004 American Association for Cancer Research

Model Organisms

Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis1

Pauli A. Puolakkainen1,2,3, Rolf A. Brekken1,4, Sabeeha Muneer4 and E. Helene Sage1

1 Department of Vascular Biology, Hope Heart Institute, and 2 Department of Medicine, University of Washington, Seattle, Washington; 3 Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland; and 4 Division of Surgical Oncology, Department of Pharmacology, and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas

Requests for reprints: Rolf A. Brekken, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-8593. Phone: (214) 648-5151; Fax: (214) 648-4940. E-mail: rolf.brekken{at}utsouthwestern.edu

SPARC, a matricellular glycoprotein, modulates cellular interaction with the extracellular matrix (ECM). Tumor growth and metastasis occur in the context of the ECM, the levels and deposition of which are controlled in part by SPARC. Tumor-derived SPARC is reported to stimulate or retard tumor progression depending on the tumor type, whereas the function of host-derived SPARC in tumorigenesis has not been explored fully. To evaluate the function of endogenous SPARC, we have examined the growth of pancreatic tumors in SPARC-null (SP–/–) mice and their wild-type (SP+/+) counterparts. Mouse pancreatic adenocarcinoma cells injected s.c. grew significantly faster in SP–/– mice than cells injected into SP+/+ animals, with mean tumor weights at sacrifice of 0.415 ± 0.08 and 0.086 ± 0.03 g (P < 0.01), respectively. Lack of endogenous SPARC resulted in decreased collagen deposition and fiber formation, alterations in the distribution of tumor-infiltrating macrophages, and decreased tumor cell apoptosis. There was no difference in microvessel density of tumors from SP–/– or SP+/+ mice. However, tumors grown in SP–/– had a lower percentage of blood vessels that expressed smooth muscle {alpha}-actin, a marker of pericytes. These data reflect the importance of ECM deposition in regulating tumor growth and demonstrate that host-derived SPARC is a critical factor in the response of host tissue to tumorigenesis.




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
S. Arnold, E. Mira, S. Muneer, G. Korpanty, A. W. Beck, S. E. Holloway, S. Manes, and R. A. Brekken
Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC
Experimental Biology and Medicine, July 1, 2008; 233(7): 860 - 873.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. Tang and I. T. Tai
A Novel Interaction between Procaspase 8 and SPARC Enhances Apoptosis and Potentiates Chemotherapy Sensitivity in Colorectal Cancers
J. Biol. Chem., November 23, 2007; 282(47): 34457 - 34467.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Mongiat, G. Ligresti, S. Marastoni, E. Lorenzon, R. Doliana, and A. Colombatti
Regulation of the Extrinsic Apoptotic Pathway by the Extracellular Matrix Glycoprotein EMILIN2
Mol. Cell. Biol., October 15, 2007; 27(20): 7176 - 7187.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Said, M. J. Socha, J. J. Olearczyk, A. A. Elmarakby, J. D. Imig, and K. Motamed
Normalization of the Ovarian Cancer Microenvironment by SPARC
Mol. Cancer Res., October 1, 2007; 5(10): 1015 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
O. J Sansom, F. C Mansergh, M. J Evans, J. A Wilkins, and A. R Clarke
Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice
Gut, October 1, 2007; 56(10): 1410 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. Mahadevan and D. D. Von Hoff
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mol. Cancer Ther., April 1, 2007; 6(4): 1186 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Said, I. Najwer, and K. Motamed
Secreted Protein Acidic and Rich in Cysteine (SPARC) Inhibits Integrin-Mediated Adhesion and Growth Factor-Dependent Survival Signaling in Ovarian Cancer
Am. J. Pathol., March 1, 2007; 170(3): 1054 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Infante, H. Matsubayashi, N. Sato, J. Tonascia, A. P. Klein, T. A. Riall, C. Yeo, C. Iacobuzio-Donahue, and M. Goggins
Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma
J. Clin. Oncol., January 20, 2007; 25(3): 319 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Taghizadeh, M. J. Tang, and I. T. Tai
Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy
Mol. Cancer Ther., January 1, 2007; 6(1): 309 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Dai, Y. Yang, V. MacLeod, X. Yue, A. C. Rapraeger, Z. Shriver, G. Venkataraman, R. Sasisekharan, and R. D. Sanderson
HSulf-1 and HSulf-2 Are Potent Inhibitors of Myeloma Tumor Growth in Vivo
J. Biol. Chem., December 2, 2005; 280(48): 40066 - 40073.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Said and K. Motamed
Absence of Host-Secreted Protein Acidic and Rich in Cysteine (SPARC) Augments Peritoneal Ovarian Carcinomatosis
Am. J. Pathol., December 1, 2005; 167(6): 1739 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. E. Koblinski, B. R. Kaplan-Singer, S. J. VanOsdol, M. Wu, J. A. Engbring, S. Wang, C. M. Goldsmith, J. T. Piper, J. G. Vostal, J. F. Harms, et al.
Endogenous Osteonectin/SPARC/BM-40 Expression Inhibits MDA-MB-231 Breast Cancer Cell Metastasis
Cancer Res., August 15, 2005; 65(16): 7370 - 7377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Q. Shi, S. Bao, J. A. Maxwell, E. D. Reese, H. S. Friedman, D. D. Bigner, X.-F. Wang, and J. N. Rich
Secreted Protein Acidic, Rich in Cysteine (SPARC), Mediates Cellular Survival of Gliomas through AKT Activation
J. Biol. Chem., December 10, 2004; 279(50): 52200 - 52209.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.